| scholarly article | Q13442814 |
| P50 | author | Sagar Lonial | Q66431075 |
| P2093 | author name string | Jing Chen | |
| Roberto D Polakiewicz | |||
| D Gary Gilliland | |||
| P Leif Bergsagel | |||
| Doriano Fabbro | |||
| Sumin Kang | |||
| Ting-Lei Gu | |||
| Ailan Guo | |||
| Jack Taunton | |||
| Shaozhong Dong | |||
| Michael S Cohen | |||
| Hanna Jean Khoury | |||
| P2860 | cites work | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells | Q21735929 |
| Rsk1 mediates a MEK-MAP kinase cell survival signal | Q22253213 | ||
| Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation | Q24291107 | ||
| C/EBPbeta phosphorylation by RSK creates a functional XEXD caspase inhibitory box critical for cell survival | Q24291845 | ||
| Frequent dysregulation of the c-maf proto-oncogene at 16q23 by translocation to an Ig locus in multiple myeloma | Q24322230 | ||
| Fibroblast growth factor receptor 3 is a negative regulator of bone growth | Q24322706 | ||
| Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity | Q24679767 | ||
| 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. | Q27863657 | ||
| RSK2 activity is regulated by its interaction with PEA-15 | Q28177939 | ||
| Chromosome translocations in multiple myeloma | Q28199347 | ||
| Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 | Q28242697 | ||
| The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts | Q28286552 | ||
| Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo | Q28294928 | ||
| Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia | Q28640044 | ||
| Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma | Q28646235 | ||
| The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells | Q28678602 | ||
| Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma | Q28678660 | ||
| Raf-1 kinase and exoenzyme S interact with 14-3-3zeta through a common site involving lysine 49. | Q33292522 | ||
| Phenotypic expression of the fibroblast growth factor receptor 3 (FGFR3) mutation P250R in a large craniosynostosis family | Q33679292 | ||
| Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. | Q33690319 | ||
| Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma | Q35938169 | ||
| Signal transduction via the MAP kinases: proceed at your own RSK. | Q36381460 | ||
| A clickable inhibitor reveals context-dependent autoactivation of p90 RSK | Q36790127 | ||
| Characterization of regulatory events associated with membrane targeting of p90 ribosomal S6 kinase 1 | Q39528760 | ||
| A phosphoserine-regulated docking site in the protein kinase RSK2 that recruits and activates PDK1. | Q39922852 | ||
| Evidence for two catalytically active kinase domains in pp90rsk | Q40018405 | ||
| BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo | Q40220439 | ||
| Structural bioinformatics-based design of selective, irreversible kinase inhibitors | Q40307105 | ||
| The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling | Q40364004 | ||
| FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies | Q40386878 | ||
| Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. | Q40577049 | ||
| Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. | Q40600637 | ||
| Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. | Q40616537 | ||
| Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations | Q40795919 | ||
| A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. | Q42109383 | ||
| Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. | Q42664840 | ||
| Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation. | Q42742643 | ||
| Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. | Q42811937 | ||
| Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. | Q45345154 | ||
| Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. | Q45345166 | ||
| The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. | Q46665949 | ||
| A MAP kinase docking site is required for phosphorylation and activation of p90(rsk)/MAPKAP kinase-1. | Q48922580 | ||
| Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. | Q49042849 | ||
| P433 | issue | 3 | |
| P921 | main subject | phosphorylation | Q242736 |
| P304 | page(s) | 201-214 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway | |
| P478 | volume | 12 |
| Q33426534 | A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma |
| Q37068772 | A Rising Cancer Prevention Target of RSK2 in Human Skin Cancer |
| Q41903436 | A combination of SILAC and nucleotide acyl phosphate labelling reveals unexpected targets of the Rsk inhibitor BI-D1870. |
| Q34362408 | A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration |
| Q30498959 | A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression |
| Q42734250 | A novel interaction between fibroblast growth factor receptor 3 and the p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation of ERK by p85 in multiple myeloma cells |
| Q30249143 | A place for precision medicine in bladder cancer: targeting the FGFRs |
| Q24632768 | Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases |
| Q35570177 | Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans |
| Q30441657 | Activation of p90 ribosomal S6 kinase by ORF45 of Kaposi's sarcoma-associated herpesvirus and its role in viral lytic replication |
| Q24297829 | An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis |
| Q30419492 | Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability |
| Q30275748 | Bacterial Expression, Purification and In Vitro Phosphorylation of Full-Length Ribosomal S6 Kinase 2 (RSK2) |
| Q50098089 | Carnitine Palmitoyltransferase 1A Has a Lysine Succinyltransferase Activity |
| Q36245320 | Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer |
| Q37234005 | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. |
| Q52719999 | Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway. |
| Q51900106 | Coffin-Lowry syndrome: a role for RSK2 in mammalian neurogenesis. |
| Q33584146 | Coordinating cellular events during spermatogenesis: a biochemical model |
| Q37854521 | Current advances in the application of proteomics in apoptosis research |
| Q37976004 | Dissecting cell death with proteomic scalpels |
| Q34645436 | Dysregulation of RNA polymerase I transcription during disease. |
| Q36632041 | Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. |
| Q27851554 | FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer |
| Q37582147 | FGFR3 silencing by siRNA inhibits invasion of A549 cells |
| Q28252845 | Factors underlying sensitivity of cancers to small-molecule kinase inhibitors |
| Q34305653 | Fibroblast and Epidermal Growth Factors Utilize Different Signaling Pathways to Induce Anchorage-independent Cell Transformation in JB6 Cl41 Mouse Skin Epidermal Cells |
| Q41910374 | Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation |
| Q38720908 | Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. |
| Q34504939 | Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer |
| Q33714250 | Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. |
| Q51298669 | Glucocorticoid mediates water avoidance stress-sensitized colon-bladder cross-talk via RSK2/PSD-95/NR2B in rats. |
| Q38733973 | IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal |
| Q52353697 | Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening. |
| Q27676158 | Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution |
| Q35015735 | Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation |
| Q92085285 | Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair |
| Q27670966 | Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor |
| Q37396056 | Interactions between FGFR2 and RSK2-implications for breast cancer prognosis. |
| Q52655388 | Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. |
| Q33743857 | Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2. |
| Q37697253 | Kinase inhibitors as potential agents in the treatment of multiple myeloma |
| Q39869836 | Mechanism of sustained activation of ribosomal S6 kinase (RSK) and ERK by kaposi sarcoma-associated herpesvirus ORF45: multiprotein complexes retain active phosphorylated ERK AND RSK and protect them from dephosphorylation |
| Q35636041 | MiR-191 Regulates Primary Human Fibroblast Proliferation and Directly Targets Multiple Oncogenes |
| Q89622427 | MicroRNA-99a Suppresses Breast Cancer Progression by Targeting FGFR3 |
| Q37415946 | Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. |
| Q34991546 | Multiple synostoses syndrome is due to a missense mutation in exon 2 of FGF9 gene |
| Q34606074 | Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. |
| Q33884709 | Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis |
| Q38462720 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy |
| Q34974049 | RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2. |
| Q30433106 | RSK in tumorigenesis: connections to steroid signaling |
| Q97421851 | RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit |
| Q30432330 | RSK2 Binding Models Delineate Key Features for Activity |
| Q37694863 | RSK2 activity mediates glioblastoma invasiveness and is a potential target for new therapeutics |
| Q48347255 | RSK2 drives cell motility by serine phosphorylation of LARG and activation of Rho GTPases |
| Q47797184 | RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia. |
| Q34072205 | RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. |
| Q30423242 | RSK2 protein suppresses integrin activation and fibronectin matrix assembly and promotes cell migration |
| Q39076265 | RSK2 regulates endocytosis of FGF receptor 1 by phosphorylation on serine 789. |
| Q37579739 | RSK2 signals through stathmin to promote microtubule dynamics and tumor metastasis |
| Q36212896 | Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. |
| Q38895271 | Ribosomal S6 kinase (RSK) modulators: a patent review |
| Q64108332 | Role of p90RSK in Kidney and Other Diseases |
| Q37802388 | Targeting RSK2 in human malignancies |
| Q39335656 | Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers |
| Q36356078 | Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3 |
| Q50091331 | The Early Dendritic Cell Signaling Induced by Virulent Francisella tularensis Strain Occurs in Phases and Involves the Activation of Extracellular Signal-Regulated Kinases (ERKs) and p38 In the Later Stage |
| Q39163272 | The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. |
| Q24315679 | The RSK family of kinases: emerging roles in cellular signalling |
| Q37223754 | The p90 ribosomal S6 kinase 2 specifically affects mitotic progression by regulating the basal level, distribution and stability of mitotic spindles |
| Q37289259 | The prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis |
| Q50787038 | The promise and challenges of targeting RSK for the treatment of cancer. |
| Q33784827 | The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling |
| Q35076678 | Treatment of a human papillomavirus type 31b-positive cell line with benzo[a]pyrene increases viral titer through activation of the Erk1/2 signaling pathway |
| Q38259322 | Triple-negative breast cancer: investigating potential molecular therapeutic target |
| Q36122105 | Tumor necrosis factor receptor-associated factor family protein 2 is a key mediator of the epidermal growth factor-induced ribosomal S6 kinase 2/cAMP-responsive element-binding protein/Fos protein signaling pathway |
| Q24300524 | Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism |
| Q28115584 | Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity |
| Q37131331 | Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells |
| Q35063920 | YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer |
| Q36224383 | microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3 |
| Q39162303 | p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms |
| Q33755364 | p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells |
| Q35083267 | p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia. |
Search more.